Quantifying Putative Retinal Gliosis in Preclinical Alzheimer's Disease
Investigative Ophthalmology & Visual Science · 2024
DOI: 10.1167/iovs.65.5.5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigative Ophthalmology & Visual Science, 2024. Verfasst von Swetha Ravichandran und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Optometry, University of Alabama at Birmingham, Birmingham, Alabama, United States. Hauptthemen laut MEDLINE: Gliosis, Alzheimer Disease, Tomography, Optical Coherence, Retinal Ganglion Cells. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Purpose
Neuroinflammation plays a significant role in the pathology of Alzheimer's disease (AD). Mouse models of AD and postmortem biopsy of patients with AD reveal retinal glial activation comparable to central nervous system immunoreactivity. We hypothesized that the surface area of putative retinal gliosis observed in vivo using en face optical coherence tomography (OCT) imaging will be larger in patients with preclinical AD versus controls.
Methods
The Spectralis II instrument was used to acquire macular centered 20 × 20 and 30 × 25-degrees spectral domain OCT images of 76 participants (132 eyes). A cohort of 22 patients with preclinical AD (40 eyes, mean age = 69 years, range = 60-80 years) and 20 control participants (32 eyes, mean age = 66 years, range = 58-82 years, P = 0.11) were included for the assessment of difference in surface area of putative retinal gliosis and retinal nerve fiber layer (RNFL) thickness. The surface area of putative retinal gliosis and RNFL thickness for the nine sectors of the Early Treatment Diabetic Retinopathy Study (ETDRS) map were compared between groups using generalized linear mixed models.
Results
The surface area of putative retinal gliosis was significantly greater in the preclinical AD group (0.97 ± 0.55 mm2) compared to controls (0.68 ± 0.40 mm2); F(1,70) = 4.41, P = 0.039; Cohen's d = 0.61. There was no significant difference between groups for RNFL thickness in the 9 ETDRS sectors, P > 0.05.
Conclusions
Our analysis shows greater putative retinal gliosis in preclinical AD compared to controls. This demonstrates putative retinal gliosis as a potential biomarker for AD-related neuroinflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- School of Optometry, University of Alabama at Birmingham, Birmingham, Alabama, United States.
- Department of Neurology, Alpert Medical School of Brown University, Providence, Rhode Island, United States.
- Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island, United States.
- George and Anne Ryan Institute for Neuroscience, University of Rhode Island, Kingston, Rhode Island, United States.
- Butler Hospital Memory and Aging Program, Providence, Rhode Island, United States.
- Alzheimer's Disease Research Center, Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Förderung
- NIA NIH HHS
Zitieren
APA
Ravichandran, S., Snyder, P. J., Alber, J., Kenny, M. R., Rothstein, A., Brown, K., Murchison, C. F., Clay, O. J., Roberson, E. D., & Arthur, E. (2024). Quantifying Putative Retinal Gliosis in Preclinical Alzheimer's Disease. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.65.5.5
Vancouver
Ravichandran S, Snyder PJ, Alber J, Kenny MR, Rothstein A, Brown K, et al. Quantifying Putative Retinal Gliosis in Preclinical Alzheimer's Disease. Investigative Ophthalmology & Visual Science. 2024. doi:10.1167/iovs.65.5.5
BibTeX
@article{Ravichandran2024,
author = {Ravichandran, Swetha and Snyder, Peter J and Alber, Jessica and Kenny, Madelyn R and Rothstein, Andrew and Brown, Keisha and Murchison, Charles F and Clay, Olivio J and Roberson, Erik D and Arthur, Edmund},
title = {Quantifying Putative Retinal Gliosis in Preclinical Alzheimer's Disease},
journal = {Investigative Ophthalmology & Visual Science},
year = {2024},
doi = {10.1167/iovs.65.5.5}
}
EUVIMED